Bladder

Tuesday, October 4, 2016

First new drug for bladder cancer approved


CANCER DIGEST – Oct. 4, 2016 – The FDA approval of Tecentriq ushers in the first new treatment for advanced bladder cancer in 30 years.

The drug works by blocking a protein tumor cells produce on their cell surfaces that prevents the immune system’s T cells from attacking the cancer cells. The protein tumors produce is known as an "immune checkpoint," and prevents T cells from recognizing and binding to the cancer cell, thus evading the T cell attack. This "checkpoint" protein is called  PD-L1 and Tecentriq binds to it allowing T cells to land and establish a beachhead to attack the cancer cell. 

Tuesday, February 2, 2016

New advice for evaluating blood in the urine for signs of cancer


CANCER DIGEST – Feb. 2, 2016 – Physicians are being advised to take a second look at blood in the urine, or hematuria, for signs of cancer, by a new report from the American College of Physicians’ High Value Care Task Force.

The Task Force issues advice for physicians on how to detect and evaluate hematuria. The report stems from research at the University of North Carolina Lineberger Comprehensive Cancer Center. 

Wednesday, November 26, 2014


Promising drug for advanced bladder cancer given breakthrough status

Genentech video. Click to view 
CANCER DIGEST – Nov. 26, 2014 – A team of British scientists are reporting made a major breakthrough with a new therapy for advanced bladder cancer - for which there have been no major treatment advances in the past 30 years.

Led by Dr. Tom Powles, consultant medical oncologist, Barts Cancer Institute, Queen Mary University of London, the researchers published early results of a small phase I study today in the journal Nature.

Tuesday, April 1, 2014


New test may indicate bladder cancer recurrence

Non-muscle invasive bladder cancer
(NMIBC) is the most common. (Fig.
courtesy of Wikipedia)
MEDICAL NEWS TODAY – Apr. 1, 2014 – A new test that measures a chemical that acts on DNA in many cell processes appears to be highly sensitive in detecting recurrence of the most common form of bladder cancer. Researchers at the University of Southern California, Norris Comprehensive Cancer Center in Los Angeles validated the test on 368 urine samples from 90 bladder cancer patients monitored over seven years. The report in the journal Clinical Cancer Research shows that the new test correctly predicted cancer recurrence 80 percent of the time, and correctly indicated no recurrence 74 percent of the time. Current methods of detecting recurrence in these patients are correct 35 percent of the time and rule out cancer accurately 15 percent of the time.

No comments:

Post a Comment